English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Accurate pre-treatment evaluation including prostate multiparametric MRI (mpMRI) and prostate biopsy is required to efficiently discriminate clinically significant prostate cancer (csPC) from clinically insignificant prostate cancer (cis PC). On the other hand, as one solution to the limitations of standard systematic transrectal ultrasonography (TRUS)-guided prostate biopsy including the underestimation of tumor aggressiveness PC such as the Gleason score (GS), the false negative result for anterior lesion, and the overtreatment for detection of cis PC such as small PC with GS 3 + 3, the MRI-ultrasound (US) fusion-guided biopsy is becoming a gradually used method for prostate-targeted biopsy.1  Therefore, the aim of this study was to report our early experience with MRI-US fusion-guided prostate biopsy in Japanese men with elevated prostate-specific antigen (PSA) levels.

Early Experience with MRI-ultrasound Fusion-guided Prostate Biopsy in Japanese Men with Elevated PSA Levels